207 related articles for article (PubMed ID: 21273047)
1. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker.
Kanemaru H; Fukushima S; Yamashita J; Honda N; Oyama R; Kakimoto A; Masuguchi S; Ishihara T; Inoue Y; Jinnin M; Ihn H
J Dermatol Sci; 2011 Mar; 61(3):187-93. PubMed ID: 21273047
[TBL] [Abstract][Full Text] [Related]
2. MIA, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Lederer M; Kaufmann M; Hein R; Stolz W; Apfel R; Bogdahn U; Buettner R
Anticancer Res; 1999; 19(4A):2691-3. PubMed ID: 10470221
[TBL] [Abstract][Full Text] [Related]
3. Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.
Weinlich G; Murr C; Richardsen L; Winkler C; Fuchs D
Dermatology; 2007; 214(1):8-14. PubMed ID: 17191041
[TBL] [Abstract][Full Text] [Related]
4. S100 serum level: a tumour marker for metastatic melanoma.
Bottoni U; Izzo P; Richetta A; Mannooranparampil TJ; Devirgiliis V; Del Giudice M; Reale MG; Frati L; Calvieri S
Melanoma Res; 2003 Aug; 13(4):427-9. PubMed ID: 12883371
[No Abstract] [Full Text] [Related]
5. Comparison of S100 protein and MIA protein as serum marker for malignant melanoma.
Djukanovic D; Hofmann U; Sucker A; Rittgen W; Schadendorf D
Anticancer Res; 2000; 20(3B):2203-7. PubMed ID: 10928178
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma.
Hofmann MA; Gussmann F; Fritsche A; Biesold S; Schicke B; Küchler I; Voit C; Trefzer U
Melanoma Res; 2009 Feb; 19(1):17-23. PubMed ID: 19104451
[TBL] [Abstract][Full Text] [Related]
7. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B.
Paschen A; Sucker A; Hill B; Moll I; Zapatka M; Nguyen XD; Sim GC; Gutmann I; Hassel J; Becker JC; Steinle A; Schadendorf D; Ugurel S
Clin Cancer Res; 2009 Aug; 15(16):5208-15. PubMed ID: 19671853
[TBL] [Abstract][Full Text] [Related]
8. Serum S-100 protein: a potentially useful prognostic marker in cutaneous melanoma.
Abraha HD; Fuller LC; Du Vivier AW; Higgins EM; Sherwood RA
Br J Dermatol; 1997 Sep; 137(3):381-5. PubMed ID: 9349333
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma.
Helfrich I; Edler L; Sucker A; Thomas M; Christian S; Schadendorf D; Augustin HG
Clin Cancer Res; 2009 Feb; 15(4):1384-92. PubMed ID: 19228739
[TBL] [Abstract][Full Text] [Related]
10. [S-100B and MIA (melanoma inhibiting activity) serum proteins: a prospective study of their value as melanoma progression markers].
Dornier C; Dousset B; Legras B; Barbaud A; Schmutz JL
Ann Dermatol Venereol; 2002 May; 129(5 Pt 1):739-40. PubMed ID: 12124520
[No Abstract] [Full Text] [Related]
11. [Serum S100B protein and stage of cutaneous melanoma: a prospective study].
Brouard M; Quillien V; Ollivier I; Lesimple T; Adamski H; Chevrant-Breton J
Ann Dermatol Venereol; 2000 Jan; 127(1):56-9. PubMed ID: 10717564
[TBL] [Abstract][Full Text] [Related]
12. Results of the determination of serum markers in patients with malignant melanoma.
Lugović L; Situm M; Buljan M; Poduje S; Sebetić K
Coll Antropol; 2007 Jan; 31 Suppl 1():7-11. PubMed ID: 17469741
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-6 and its surrogate C-reactive protein are useful serum markers for monitoring metastasized malignant melanoma.
Deichmann M; Benner A; Waldmann V; Bock M; Jäckel A; Näher H
J Exp Clin Cancer Res; 2000 Sep; 19(3):301-7. PubMed ID: 11144523
[TBL] [Abstract][Full Text] [Related]
14. Molecular staging by multimarker reverse transcriptase-polymerase chain reaction assay of lymphatic drainage and blood from melanoma patients after lymph node dissection.
Rutkowski P; Nowecki ZI; Kulik J; Ruka W; Siedlecki JA
Melanoma Res; 2008 Aug; 18(4):246-52. PubMed ID: 18626308
[TBL] [Abstract][Full Text] [Related]
15. Simultaneous measurement of circulating intercellular adhesion molecule-1 and serum copper zinc superoxide dismutase activity in patients with malignant melanoma.
Wollina U; Karte K; Olbertz K; Hipler UC
Oncol Rep; 1998; 5(2):473-6. PubMed ID: 9468582
[TBL] [Abstract][Full Text] [Related]
16. [Laboratory markers of melanoma progression].
Bánfalvi T; Edesné MB; Gergye M; Udvarhelyi N; Orosz Z; Gilde K; Kremmer T; Ottó S; Tímár J
Magy Onkol; 2003; 47(1):89-104. PubMed ID: 12704461
[TBL] [Abstract][Full Text] [Related]
17. Molecular and biochemical testing in stage III melanoma: multimarker reverse transcriptase-polymerase chain reaction assay of lymph fluid after lymph node dissection and preoperative serum lactate dehydrogenase level.
Nowecki ZI; Rutkowski P; Kulik J; Siedlecki JA; Ruka W
Br J Dermatol; 2008 Sep; 159(3):597-605. PubMed ID: 18616789
[TBL] [Abstract][Full Text] [Related]
18. A case of malignant melanoma: disease progression correlated with serum levels of 5-S-Cysteinyldopa (5-S-CD) and intercellular adhesion molecule-1 (ICAM-1).
Ye Z; Kageshita T; Ishihara T; Ito S; Ono T
J Dermatol; 1995 May; 22(5):370-5. PubMed ID: 7673560
[TBL] [Abstract][Full Text] [Related]
19. Melanoma-inhibiting activity, a novel serum marker for progression of malignant melanoma.
Bosserhoff AK; Kaufmann M; Kaluza B; Bartke I; Zirngibl H; Hein R; Stolz W; Buettner R
Cancer Res; 1997 Aug; 57(15):3149-53. PubMed ID: 9242442
[TBL] [Abstract][Full Text] [Related]
20. Utility of FDG PET/CT and brain MRI in melanoma patients with increased serum S-100B level during follow-up.
Aukema TS; Olmos RA; Korse CM; Kroon BB; Wouters MW; Vogel WV; Bonfrer JM; Nieweg OE
Ann Surg Oncol; 2010 Jun; 17(6):1657-61. PubMed ID: 20151211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]